继尼斯批准后，英国国家医疗服务体系 (NHS) 将广泛推广 Tisagenlecleucel (Kymriah) 血癌治疗。 NHS in England to widely roll out Tisagenlecleucel (Kymriah) blood cancer treatment, following Nice's approval.

挽救生命的血癌治疗药物 Tisagenlecleucel (Kymriah) 将在获得尼斯批准后在英国 NHS 广泛推广。 Life-saving blood cancer treatment, Tisagenlecleucel (Kymriah), set to be widely rolled out on NHS in England following Nice's approval. 个性化的 Car-T 疗法可以重新编程患者的免疫系统细胞来对抗癌症。 A personalised Car-T therapy, it reprograms patients' immune system cells to target cancer. 自 2018 年起，尼斯癌症药物基金已为 B 细胞急性淋巴细胞白血病患者提供该药物，并建议 25 岁及以下符合条件的患者常规推广该药物。 Currently available for B-cell acute lymphoblastic leukaemia patients via Cancer Drugs Fund since 2018, Nice has recommended its routine rollout for eligible patients aged 25 and under.